A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Fox Chase Cancer Center, Philadelphia

American Oncology Partners of Maryland P.A, Bethesda

Saint Agnes Hospital, Baltimore

Woodlands Medical Specialists- Pensacola, Pensacola

Tri-Health Cancer Institute-Medical Oncology and Hematology Westside, Cincinnati

Avera Cancer Institute, Sioux Falls

Kansas City Veterans Affairs Medical Center, Kansas City

Central Care Cancer Center, Bolivar

Texas Oncology- Presbyterian Cancer Center Dallas, Dallas

Texas Oncology -Tyler, Tyler

Texas Oncology-San Antonio Northwest, San Antonio

US Oncology Research, Colorado Springs

Arizona Oncology Associates, Tucson

Comprehensive Cancer Center of Nevada, Henderson

Innovative Clinical Research, Santa Ana

Compassionate Care Research Group, Inc., Fountain Valley

Willamette Valley Cancer Institute and Research Center - Springfield, Springfield

Los Angeles Cancer Network/(Formerly -Pacific Cancer Medical Center), Anaheim

Winship Cancer Institute of Emory University, Atlanta

Investigator Clinical Research - Indiana, Indianapolis

Millennium Physicians Association, Shenandoah